Drug Delivery Devices Market Size, Share, and Trends

Drug Delivery Devices Market (By Route of Administration: Oral, Ocular, Inhalation, Nasal, Injectable, , Topical, and Others; By Application: Cardiovascular, Diabetes, Cancer, Infectious Diseases, and Others; By End Users: Hospitals, Ambulatory Services, and Home Healthcare) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

  • Last Updated : December 2022
  • Report Code : 1395
  • Category : Healthcare

The global drug delivery devices market size was valued at USD 269.8 billion in 2022 and it is predicted to hit USD 421.4 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 4.56% during the forecast period 2023 to 2032. In 2022, North America market has held highest revenue share of over 38%.

Drug Delivery Devices Market Size 2023 to 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Growth Factors

The technological advancements in the medical device manufacturing has led to the development of innovative drug delivery devices that ensures right amount of medicine is administered to the patient at the right time. Moreover, the rising burden of chronic diseases such as diabetes, CVDs, cancer, and COPD is fueling the demand for the drug delivery devices. According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. Moreover, the CVD accounted for around 32% of the global deaths in 2019. The rapid growth of the biopharmaceuticals and development of various drugs that can cure the chronic diseases efficiently fostered the demand for the drug delivery devices across the globe.

The rapid growth of the biopharmaceutical industry is resulting in the development of various new drugs that are effective in treatment of various diseases. The rising investments by the drug manufacturers in the clinical trials and the active role played by the various authorities like FDA and EMA is boosting the development of innovative new drugs. The new to the market drugs sometimes requires innovative delivery devices, which boosts the need for the various drug delivery devices. Moreover, the presence of several top players and the developmental strategies like acquisitions, mergers, collaborations, and new product launches augments the market growth. Furthermore, the increasing investments in the marketing activities by the market players positively impact the market growth.

Drug Delivery Devices Market  Scope

Report Highlights Details
Market Size USD 421.4 Billion by 2032
Growth Rate CAGR of 4.56% From 2023 to 2032
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Route of Administration, Application, End User, Region
Companies Mentioned Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV

 

Route of Administration Insights

Based on the route of administration, the oral segment dominated the largest market share in 2022. This is attributed to the increased popularity of the oral drug delivery as it is pain-free, convenient for the patients, economical, non-invasive, and can be self-administered. Moreover, the majority of the drugs or medicines are available in the liquid, powder, and tablet forms, which are generally administered through the oral route. Hence, the huge availability of the medicines that are administered through the oral route has augmented the segment growth. Therefore, the rapid growth of the biopharmaceutical medicines had positively impacted the market growth in the past few years. Therefore, the rapid growth of the biopharmaceutical medicines had positively impacted the market growth in the past few years.

The topical is estimated to be the most opportunistic market during the forecast period. The benefits such as non-invasiveness, ease of use, convenience, and painless delivery associated with the topical route of administration is expected to drive the market growth. The topical route administration is further characterized by the introduction of time-controlled system which further boosts its demand.

Application Insights

Based on the application, the cancer segment dominated the largest market share in 2022. This is attributed to the increased prevalence of cancer among the population. The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. Hence, the increased prevalence of various cancer such as breast cancer, lungs cancer, bowel cancer, and womb cancer are the major drivers of this segment.

The cardiovascular segment is estimated to be the fastest-growing segment during the forecast period. The rising prevalence of CVDs among the population owing to the unhealthy food habits and inactivity is boosting the growth of this segment. According to the World Health Organization, CVDs accounted for 32% of the global deaths in 2019.

End User Insights

Based on the end user, the hospitals segment has held revenue share of over 29% in 2022. This is due to the increased penetration of the hospitals across the global. The rising investments by the government and the corporate sector in the development of the hospitals had contributed to the growth of this segment. Moreover, the increased number of hospital admissions is further fueling the segment’s growth.

The diagnostics senters segment has generated revenue share of 25% in 2022.

Drug Delivery Devices Market Share, By End User, 2020 (%)

On the other hand, the home healthcare segment is estimated to be the most opportunistic market during the forecast period. The increasing geriatric population, increased disposable income, rising demand for getting the treatment at home, and increased awareness regarding the hospital acquired infections are the major drivers of this segment.

Region Insights

Based on region, North America accounted largest revenue share in 2022. This is attributed to the rising prevalence of various chronic diseases such as diabetes, cancer, and CVDs in US. Moreover, the increased health consciousness and increased healthcare expenditure in US has boosted the growth of the market. In 2018, the per capita healthcare expenditure was more than US$ 10,500. The increased awareness regarding the availability of various innovative drug delivery devices like wearable injectors and pen injectors has significantly contributed towards the growth of the drug delivery devices in North America.

Drug Delivery Devices Market Share, By Region, 2020 (%)

Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the rising prevalence of various diseases due to the changing consumption pattern and unhealthy food habits of the population. Moreover, the rapidly growing geriatric population is expected to fuel the market demand as the old age people are more prone to the diseases. According to the United Nations, 80% of the global geriatric population will be living in low and middle-income countries.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

The various developmental strategies like acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Drug Delivery Devices Market  Companies

  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson and Johnson Private Ltd
  • Novartis AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Uniqure NV

Segments Covered in the Report

By Route of Administration

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Topical
  • Others

By Application

  • Cardiovascular
  • Diabetes
  • Cancer
  • Infectious Diseases
  • Others

By End User

  • Hospitals
  • Ambulatory Services
  • Home Healthcare

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Frequently Asked Questions

According to Precedence Research, the global drug delivery devices market size was reached at USD 269.8 billion in 2022 and is expected to reach USD 421.4 billion by 2032.

The global drug delivery devices market is growing at a CAGR of 4.56% during the forecast period 2023 to 2032.

The global drug delivery devices market is primarily driven by the rising prevalence of various chronic diseases such as cancer, diabetes, and cardiovascular diseases among the global population.

Some of the prominent players in the global drug and gene delivery devices market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV.

The North America dominated the global drug delivery devices market in 2022 and will lead during the forecast period.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Delivery Devices Market 

5.1. COVID-19 Landscape: Drug Delivery Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Delivery Devices Market, By Route of Administration

8.1. Drug Delivery Devices Market, by Route of Administration Type, 2023-2032

8.1.1. Oral

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Ocular

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Inhalation

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Nasal

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Injectable

8.1.5.1. Market Revenue and Forecast (2021-2032)

8.1.6. Topical

8.1.6.1. Market Revenue and Forecast (2021-2032)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Drug Delivery Devices Market, By Application

9.1. Drug Delivery Devices Market, by Application, 2023-2032

9.1.1. Cardiovascular

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Diabetes

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Cancer

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Drug Delivery Devices Market, By End User 

10.1. Drug Delivery Devices Market, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Ambulatory Services

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Home Healthcare

10.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Drug Delivery Devices Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.1.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.3. Market Revenue and Forecast, by End User (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.2.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.3.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.6.3. Market Revenue and Forecast, by End User (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.7.3. Market Revenue and Forecast, by End User (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.3. Market Revenue and Forecast, by End User (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.4.3. Market Revenue and Forecast, by End User (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Route of Administration (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.5.3. Market Revenue and Forecast, by End User (2021-2032)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. F. Hoffmann-La Roche Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson and Johnson Private Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Becton, Dickinson and Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Uniqure NV

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client